Journal: Frontiers in physiology

Article Title: Potential biomarkers and immune cell infiltration involved in aortic valve calcification identified through integrated bioinformatics analysis.

doi: 10.3389/fphys.2022.944551

Figure Lengend Snippet: FIGURE 5 Validation of key genes SCG2 and CCL19. (A,B) Validation of the expression and receiver operating characteristic (ROC) curve of SCG2 and CCL19 in the merged metadata cohort. (C,D) Validation of the expression of SCG2 and CCL19 and ROC curve for evaluating the discriminatory accuracy of SCG2 and CCL19 in the validation dataset GSE83453. (E,F) GSEA analysis result show the top ten enrichment terms (GO and KEGG respectively) of regrouped high SCG2 expression group. (G,H) GSEA analysis result show the top ten enrichment terms (GO and KEGG respectively) of regrouped high CCL19 expression group. **p < 0.01, ****p < 0.0001.

Article Snippet: Sections were deparaffinated, blocked, and incubated with the primary anti-SCG2 antibody (Proteintech, 20357-1-AP) or Anti-CCL19 Antibody (Proteintech, 13397-1-AP) at 4°C overnight.

Techniques: Biomarker Discovery, Expressing

Journal: Frontiers in physiology

Article Title: Potential biomarkers and immune cell infiltration involved in aortic valve calcification identified through integrated bioinformatics analysis.

doi: 10.3389/fphys.2022.944551

Figure Lengend Snippet: FIGURE 7 Correlation analysis between key genes and immune cells. (A) Correlation analysis for SCG2. (B) Correlation analysis for CCL19. Size of the dots represents the strength of the correlation between genes and immune cells, and color of the dots represents p-value. p < 0.05 was considered statistically significant. (C,D) Scatter plot showing the correlation between SCG2/CCL19 and immune cells. The X-axis represents the mRNA expression level of genes, the Y-axis represents the expression abundance of immune cells, and the R value represents the correlation coefficient.

Article Snippet: Sections were deparaffinated, blocked, and incubated with the primary anti-SCG2 antibody (Proteintech, 20357-1-AP) or Anti-CCL19 Antibody (Proteintech, 13397-1-AP) at 4°C overnight.

Techniques: Expressing

Journal: Frontiers in physiology

Article Title: Potential biomarkers and immune cell infiltration involved in aortic valve calcification identified through integrated bioinformatics analysis.

doi: 10.3389/fphys.2022.944551

Figure Lengend Snippet: FIGURE 8 Validation at single cell level and tissue level. (A) tSNE visualization of clustering revealed 12 cell populations. Cell population identities were determined based on marker gene expression. (B) Heatmap of top 5 marker genes for each cell cluster. (C) Heatmap shows the expression of SCG2 and CCL19 in 12 clusters of cells in CAVD group and normal control group, respectively. The transition from blue to orange represents the increased expression level. (D) The heatmap of GSEA analysis results shows the hallmark functional pathways enriched in each of the calcified or normal aortic valve cell clusters. The transition from blue to red indicates the increased enrichment of pathways. (E) H and E staining and immunohistochemical staining of human aortic valve tissue sections. Macroscopic and micrographs views of immunohistochemical staining of SCG2 and CCL19 from left to right. (F) Histograms of quantitative immunohistochemical staining results. The expression of SCG2 and CCL19 was significantly increased in CAVD group. AUC: Area under the ROC curve; 95% CI: 95% confidence interval; Norm: normal; CAVD: calcific aortic valve disease; VICs: valvular interstitial cells; VECs: valvular endothelial cell; TCs: T cells. ***p < 0.001.

Article Snippet: Sections were deparaffinated, blocked, and incubated with the primary anti-SCG2 antibody (Proteintech, 20357-1-AP) or Anti-CCL19 Antibody (Proteintech, 13397-1-AP) at 4°C overnight.

Techniques: Biomarker Discovery, Marker, Gene Expression, Expressing, Control, Functional Assay, Staining, Immunohistochemical staining

Journal: Cell Death & Disease

Article Title: CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer

doi: 10.1038/s41419-018-1010-2

Figure Lengend Snippet: a CCL19 expression level in tumor tissues and the paired normal tissues was evaluated by immunohistochemical staining with tissue microarray (scale: 200 μm). b CCL19 is lowly expressed in cancer tissues compared with normal tissues in tissue microarray. c CCL19 expression level and MVD (CD31-positive cell) in tumor tissues (scale: 200 μm). d Expression correlation of CCL19 and MVD was analyzed in 78 CRC patients ( P = 0.0002). Data represent the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Antibodies of IHC analysis included anti-CCL19 (AF361, R&D) and anti-CD31 (sc-376764, Santa Cruz Biotechnology) antibody.

Techniques: Expressing, Immunohistochemical staining, Staining, Microarray

Journal: Cell Death & Disease

Article Title: CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer

doi: 10.1038/s41419-018-1010-2

Figure Lengend Snippet: a Images of xenografts in nude mice and Balb/c mice. b Tumor volume measured per week in different groups. c Images of IHC staining of CD31 of xenografts in nude mice and Balb/c mice. d Tumor weight in different groups (mg). e Number of microvessels in different groups (scale: 200 μm). Data are presented as the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Antibodies of IHC analysis included anti-CCL19 (AF361, R&D) and anti-CD31 (sc-376764, Santa Cruz Biotechnology) antibody.

Techniques: Immunohistochemistry

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: Time course of C-C chemokine ligand 19 (CCL19) mRNA expression in rats' TGs following the injection of nerve growth factor (NGF)-related reagents. (The statistical analysis results related to the image are shown in ).

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Expressing, Injection

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: p -value of C-C chemokine ligand 19 (CCL19) mRNA expression in rats' TGs following the injection of nerve growth factor (NGF)-related reagents.

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Expressing, Injection

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: ( A ) Immunofluorescence results of CCL19 protein expression after injection of NGF or normal saline into rats' trigeminal ganglia (TGs) 3 days after initiation of tooth movement. ( a ) Neurons expressing CCL19 (green) after injection of normal saline on day 3 after initiation of tooth movement. ( b ) Nuclei (blue) after injection of normal saline on day 3. ( c ) Overlap of ( A ) and ( B ). ( d–f ) The same labeling as in ( a–c ) but after injection of NGF on day 3. ( B ) Time course of CCL19 protein expression in TGs following the injection of NGF or normal saline after experimental tooth movement. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Immunofluorescence, Expressing, Injection, Saline, Labeling

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: ( A ) Calcitonin gene-related peptide (CGRP) protein expression levels in TGs following different interventions after experimental tooth movement. ( B ) CCL19 protein expression levels in TGs following different interventions after experimental tooth movement. ( C ) Comparison of immunofluorescence mean gray value of CGRP and CCL19 relative expression. ( D ) Immunofluorescence results of protein expression after injection on NGF, anti-NGF antibody, and normal saline into forced rats' TGs on the 3rd day after tooth movement. ( a, e, i ) Neurons expressing CGRP (green) after injection of related reagents. ( b, f, j ) Neurons expressing CCL19 (yellow). ( c, g, k ) Nuclei (blue) after injection of related reagents on day 3. ( d, h, l ) Overlap of ( a + b + c ), ( e + f + g ), and ( i + j + k ). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Expressing, Comparison, Immunofluorescence, Injection, Saline

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: Changes in pain expressed as the bite force of rats over time after injection of CCL19 and anti-CCL19 antibody. (The statistical analysis results related to the image are shown in ).

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Injection

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: p -value of bite force of rats over time after injection of CCL19 and anti-CCL19 antibody.

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Injection

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: Changes in pain expressed as the bite force modulated by NGF via CCL19 over time. (The statistical analysis results related to the image are shown in ).

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques:

Journal: Frontiers in Neurology

Article Title: Nerve Growth Factor Enhances Tooth Mechanical Hyperalgesia Through C-C Chemokine Ligand 19 in Rats

doi: 10.3389/fneur.2021.540660

Figure Lengend Snippet: p -value of bite force of rats over time after injection of CCL19/NGF-related reagents.

Article Snippet: This was followed by inoculations into the TGs of 10 μl of 0.6 μg/μl recombinant rat CCL19 beta protein (R&D Systems, USA) in PBS, 10 μl of 0.6 μg/μl rat CCL19 beta antibody (R&D Systems, USA) in PBS, or 10 μl of normal saline solution on days 1, 3, 5, 7, and 14.

Techniques: Injection